RXII Key Stats
|Revenue (Quarterly YoY Growth)||61.40%|
|EPS Diluted (TTM)||-3.887|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-20.13M|
|Gross Profit Margin (Quarterly)|
|Profit Margin (Quarterly)||-2238%|
|Dividend Yield (TTM)||0%|
|Payout Ratio (TTM) Pro||Go Pro|
- RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period PR Newswire Dec 4
- Galena Biopharma to Present at the Oppenheimer 24th Annual Healthcare Conference noodls Dec 4
- Rxi Pharmaceuticals, Significant Upside Of 300% Is Expected In Coming Months Dec 3
- RXi Pharmaceuticals to Present at the Piper Jaffray 25th Annual Healthcare Conference PR Newswire Nov 27
- Galena Biopharma to Present at the 25th Annual Piper Jaffray Healthcare Conference noodls Nov 26
- RXi Pharmaceuticals Corporation and Ethicor Ltd. Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision PR Newswire Nov 18
- RXI PHARMACEUTICALS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Nov 14
- RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2013 PR Newswire Nov 14
- RXI PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report Nov 14
- RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery PR Newswire Nov 13
RXII Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). RXi Pharmaceuticals is up 22.36% over the last year vs S&P 500 Total Return up 26.87%, Galena Biopharma up 122.3%, and Alnylam Pharmaceuticals up 217.0%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for RXII
Pro Strategies Featuring RXII
Did RXi Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
RXi Pharmaceuticals Corp is a biotechnology company. Its main business activities are discovering, developing and commercializing therapies based on its proprietary, new-generation RNA interference platform.